Patents Assigned to Cornell Research Foundation, Inc.
-
Patent number: 10612092Abstract: A method for assessing risk of losing a transplanted organ by a patient having an episode of acute rejection of the transplanted organ is described. The method includes obtaining from the patient a cell sample from the transplanted organ or peripheral blood, determining a level of FOXP3 in the cell sample, and correlating the level with the risk of loss of the transplanted organ, wherein, compared to a control level, a significantly greater level of FOXP3 in the cell sample from the transplanted organ or a significantly lower level of FOXP3 in the cell sample from the peripheral blood correlates with a decreased risk of loss of the transplanted organ.Type: GrantFiled: December 12, 2016Date of Patent: April 7, 2020Assignee: Cornell Research Foundation, Inc.Inventor: Manikkam Suthanthiran
-
Patent number: 10584182Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.Type: GrantFiled: March 11, 2016Date of Patent: March 10, 2020Assignee: Cornell Research Foundation, Inc.Inventors: Hazel H. Szeto, Kesheng Zhao, Hugh Robertson, Alex V. Birk
-
Publication number: 20200038472Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: ApplicationFiled: September 12, 2019Publication date: February 6, 2020Applicants: Cornell Research Foundation, Inc., Institut De Recherches Cliniques de MontrealInventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
-
Patent number: 10550415Abstract: The present invention relates to a system for production of ATP. This system is comprised of a support and one or more enzymes coupled to that support which are capable of collectively producing ATP from glucose or fructose metabolism. The present invention is additionally directed to a device, which includes the system, and to a method for carrying out a reaction involving the conversion of ATP to ADP using the system.Type: GrantFiled: October 16, 2008Date of Patent: February 4, 2020Assignee: Cornell Research Foundation, Inc.Inventor: Alexander Travis
-
Patent number: 10485807Abstract: The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and/or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes.Type: GrantFiled: November 15, 2016Date of Patent: November 26, 2019Assignee: Cornell Research Foundation, Inc.Inventors: Steven A. Goldman, Fraser Sim
-
Publication number: 20190328821Abstract: The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a or 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.Type: ApplicationFiled: April 19, 2018Publication date: October 31, 2019Applicant: Cornell Research Foundation, Inc.Inventor: Hazel H. Szeto
-
Patent number: 10426600Abstract: The present invention relates to a first intraocular lens (120) embodiment having a retainer plate (124) with an annular region surrounding a central opening and an optical lens (122) removably attached to the retainer plate within the central opening. Also disclosed is a second intraocular lens embodiment having a retainer plate with a porous or perforated annular region surrounding a central opening. An optical lens (122) is integral with the retainer plate (124) within the central opening. Methods of implanting these intraocular lens (120) embodiments into a patient's eye are disclosed. Also described here are methods of replacing the first intraocular lens embodiment after it has been implanted in a patient's eye.Type: GrantFiled: July 21, 2005Date of Patent: October 1, 2019Assignees: University of Houston, Cornell Research Foundation, Inc.Inventors: D. Jackson Coleman, Adrian Glasser
-
Patent number: 10406262Abstract: The present invention relates to an article fabrication system having a plurality of material deposition tools containing one or more materials useful in fabricating the article, and a material deposition device having a tool interface for receiving one of the material deposition tools. A system controller is operably connected to the material deposition device to control operation of the material deposition device. Also disclosed is a method of fabricating an article using the system of the invention and a method of fabricating a living three-dimensional structure.Type: GrantFiled: June 29, 2018Date of Patent: September 10, 2019Assignee: Cornell Research Foundation, Inc.Inventors: Lawrence Bonassar, Hod Lipson, Daniel L. Cohen, Evan Malone
-
Patent number: 10301661Abstract: The present invention relates to an isolated DNA molecule encoding a fagopyritol synthase. A method for producing a fagopyritol, an insulin mediator, an insulin mediator analog, an insulin mediator homolog, or an insulin mediator inhibitor is also described. The method includes providing a fagopyritol synthase, providing a substrate comprising a galactosyl donor and a galactosyl acceptor, and combining the fagopyritol synthase with the substrate under conditions effective produce a fagopyritol, an insulin mediator, an insulin mediator analog, an insulin mediator homolog, or an insulin mediator inhibitor.Type: GrantFiled: February 14, 2018Date of Patent: May 28, 2019Assignee: Cornell Research Foundation, Inc.Inventors: Ralph L. Obendorf, Takashi Ueda
-
Patent number: 10258686Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: GrantFiled: February 5, 2018Date of Patent: April 16, 2019Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEAS CONTROL AND PREVENTIONInventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
-
Patent number: 10190095Abstract: One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types.Type: GrantFiled: May 23, 2016Date of Patent: January 29, 2019Assignee: Cornell Research Foundation, Inc.Inventors: Steven A. Goldman, Neeta Singh Roy, Martha Windrem
-
Patent number: 10131938Abstract: The present invention is directed to a method of designing a plurality of capture oligonucleotide probes for use on a support to which complementary oligonucleotide probes will hybridize with little mismatch, where the plural capture oligonucleotide probes have melting temperatures within a narrow range. The present invention further relates to an oligonucleotide array comprising of a support with the plurality of oligonucleotide probes immobilized on the support, a method of using the support to detect single-base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences, and a kit for such detection, which includes the support on which the oligonucleotides have been immobilized.Type: GrantFiled: July 7, 2017Date of Patent: November 20, 2018Assignee: Cornell Research Foundation, Inc.Inventors: Francis Barany, Monib Zirvi, Norman P. Gerry, Reyna Favis, Richard Kliman
-
Publication number: 20180258386Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.Type: ApplicationFiled: February 27, 2018Publication date: September 13, 2018Applicants: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer ResearchInventors: Shahin RAFII, Fan ZHANG, Marco SEANDEL
-
Patent number: 10034964Abstract: The present invention relates to an article fabrication system having a plurality of material deposition tools containing one or more materials useful in fabricating the article, and a material deposition device having a tool interface for receiving one of the material deposition tools. A system controller is operably connected to the material deposition device to control operation of the material deposition device. Also disclosed is a method of fabricating an article using the system of the invention and a method of fabricating a living three-dimensional structure.Type: GrantFiled: December 10, 2015Date of Patent: July 31, 2018Assignee: Cornell Research Foundation, Inc.Inventors: Lawrence Bonassar, Hod Lipson, Daniel L. Cohen, Evan Malone
-
Publication number: 20180186867Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: ApplicationFiled: February 20, 2018Publication date: July 5, 2018Applicants: U.S. Government represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz - FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 9950026Abstract: The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a or 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.Type: GrantFiled: December 1, 2015Date of Patent: April 24, 2018Assignee: CORNELL RESEARCH FOUNDATION, INC.Inventor: Hazel H. Szeto
-
Patent number: 9944897Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.Type: GrantFiled: May 20, 2013Date of Patent: April 17, 2018Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer ResearchInventors: Shahin Rafii, Fan Zhang, Marco Seandel
-
Patent number: 9932391Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: October 25, 2016Date of Patent: April 3, 2018Assignees: Cornell Research Foundation, Inc., The Regents of the University of California, The United States of America represented by the Department of Veterans Affairs, Fundaçäo Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 9926581Abstract: The present invention relates to an isolated DNA molecule encoding a fagopyritol synthase. A method for producing a fagopyritol, an insulin mediator, an insulin mediator analog, an insulin mediator homolog, or an insulin mediator inhibitor is also described. The method includes providing a fagopyritol synthase, providing a substrate comprising a galactosyl donor and a galactosyl acceptor, and combining the fagopyritol synthase with the substrate under conditions effective produce a fagopyritol, an insulin mediator, an insulin mediator analog, an insulin mediator homolog, or an insulin mediator inhibitor.Type: GrantFiled: June 27, 2016Date of Patent: March 27, 2018Assignee: Cornell Research Foundation, Inc.Inventors: Ralph L. Obendorf, Takashi Ueda
-
Patent number: 9913892Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: GrantFiled: October 6, 2014Date of Patent: March 13, 2018Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman